Brokerages Set Illumina, Inc. (NASDAQ:ILMN) PT at $354.35

Share on StockTwits

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average recommendation of “Buy” from the seventeen research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $341.15.

Several equities analysts have recently commented on the stock. BidaskClub cut shares of Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday. Bank of America assumed coverage on shares of Zai Lab in a research report on Friday. They issued a “buy” rating for the company. Wolfe Research assumed coverage on shares of Waters in a research report on Thursday, May 30th. They issued an “underperform” rating for the company. Cowen boosted their target price on shares of Solaredge Technologies from $65.00 to $74.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Canaccord Genuity boosted their target price on shares of Cogeco Communications from C$97.00 to C$104.00 and gave the company a “buy” rating in a research report on Friday.

In related news, SVP Charles Dadswell sold 124 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total transaction of $38,659.48. Following the completion of the transaction, the senior vice president now directly owns 8,086 shares in the company, valued at approximately $2,520,972.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $376.50, for a total transaction of $1,242,450.00. Following the transaction, the director now owns 272,616 shares of the company’s stock, valued at $102,639,924. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,291 shares of company stock valued at $19,459,234. 0.38% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Colony Group LLC grew its holdings in Illumina by 3.3% during the 4th quarter. Colony Group LLC now owns 1,172 shares of the life sciences company’s stock worth $352,000 after acquiring an additional 37 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the last quarter. Sage Capital Advisors llc boosted its stake in shares of Illumina by 0.7% in the 1st quarter. Sage Capital Advisors llc now owns 5,887 shares of the life sciences company’s stock valued at $1,829,000 after purchasing an additional 40 shares during the last quarter. Sterling Investment Advisors Ltd. boosted its stake in shares of Illumina by 2.0% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 2,090 shares of the life sciences company’s stock valued at $649,000 after purchasing an additional 40 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its stake in shares of Illumina by 1.8% in the 1st quarter. LS Investment Advisors LLC now owns 2,502 shares of the life sciences company’s stock valued at $777,000 after purchasing an additional 45 shares during the last quarter. 89.69% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:ILMN traded down $58.61 during midday trading on Friday, hitting $305.05. The stock had a trading volume of 8,474,211 shares, compared to its average volume of 880,816. The stock has a 50-day moving average price of $344.09. The company has a market capitalization of $53.46 billion, a P/E ratio of 53.33, a P/E/G ratio of 2.53 and a beta of 1.15. The company has a quick ratio of 3.33, a current ratio of 3.66 and a debt-to-equity ratio of 0.27. Illumina has a fifty-two week low of $268.62 and a fifty-two week high of $380.76.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.45 EPS. As a group, equities research analysts expect that Illumina will post 6.68 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Yield Curve

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.